We propose that the FTO/OGDHL/FASN/ERK signaling axis enriches our current understanding of ccRCC progression and metabolic reprogramming and may serve as a novel therapeutic target for ccRCC. This evidence concerns the gene FTO and nonpapillary renal cell carcinoma.